Jubilant Pharmova Ltd (JUBLPHARMA) Financials - Quarterly Results, Profit & Loss, Balance Sheet, Cash Flow Jubilant Pharmova Ltd reported sales of ₹2,229 Cr, operating profit of ₹248 Cr (OPM 11%) and net profit of ₹56 Cr for the quarter ended Jun 2026. Figures in ₹ crore, consolidated where available.
JUBLPHARMA quarterly results (₹ Cr) Metric Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sales 1,752 1,822 1,929 1,901 1,966 2,122 2,290 2,229 Expenses 1,463 1,535 1,584 1,611 1,625 1,833 1,951 1,981 Operating Profit 289 287 345 290 341 289 339 248 OPM 17% 16% 18% 15% 17% 14% 15% 11% Other Income 8 -10 9 12 4 -19 10 20 Interest 61 56 53 49 50 56 56 54 Depreciation 91 91 95 98 105 121 117 127 Profit before tax 144 130 206 154 190 93 176 86 Tax 29% 23% 27% 34% 37% 40% 32% 35% Net Profit 102 101 151 102 120 56 119 56 EPS in Rs 6.45 6.33 9.64 6.46 7.55 3.51 7.5 3.55
JUBLPHARMA profit & loss, annual (₹ Cr) Metric Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM Sales 6,130 6,282 6,703 7,234 8,280 8,608 Expenses 4,980 5,503 5,802 6,061 7,020 7,390 Operating Profit 1,150 779 901 1,173 1,260 1,218 OPM 19% 12% 13% 16% 15% 14% Other Income 8 -9 -76 416 7 15 Interest 145 188 272 240 212 217 Depreciation 382 554 382 369 440 470 Profit before tax 630 28 170 981 614 546 Tax 34% 333% 57% 15% 35% - Net Profit 413 -65 73 836 398 351 EPS in Rs 25.98 -3.83 4.84 52.69 25.02 22.11 Dividend Payout 19% -130% 102% 9% 20% -
JUBLPHARMA balance sheet (₹ Cr) Metric Mar 2023 Mar 2024 Mar 2025 Sep 2025 Mar 2026 Equity Capital 16 16 16 16 16 Reserves 5,383 5,418 6,239 6,576 7,077 Borrowings 3,677 3,664 2,731 2,883 3,615 Other Liabilities 1,853 2,240 3,598 4,047 4,564 Total Liabilities 10,929 11,338 12,584 13,521 15,272 Fixed Assets 5,183 5,091 5,176 7,354 6,966 CWIP 1,562 2,103 3,630 2,344 4,040 Investments 256 42 44 45 61 Other Assets 3,928 4,101 3,735 3,778 4,205 Total Assets 10,929 11,338 12,584 13,521 15,272
JUBLPHARMA cash flows (₹ Cr) Metric Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 Cash from Operating Activity 838 661 971 1,072 1,227 Cash from Investing Activity -323 -474 -596 512 -1,143 Cash from Financing Activity -33 -157 -432 -1,453 95 Net Cash Flow 482 30 -58 132 179 Free Cash Flow 241 -135 83 -38 -120 CFO/OP 90% 111% 131% 112% 114%
JUBLPHARMA ratios Metric Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 Debtor Days 55 56 50 45 47 Inventory Days 308 268 220 178 170 Days Payable 139 160 146 158 170 Cash Conversion Cycle 224 165 124 65 47 Working Capital Days 56 57 56 16 13 ROCE 10% 3% 7% 10% 9%